Quality measures in high-risk pregnancies: Executive Summary of a Cooperative Workshop of the Society for Maternal-Fetal Medicine, National Institute of Child Health and Human Development, and the American College of Obstetricians and Gynecologists

American Journal of Obstetrics and Gynecology

Volumn 217, Issue 4, 2017, Pages B2-B25

  Iriye, Brian K ^a   Gregory, Kimberly D ^b   Saade, George R ^c   Grobman, William A ^d   Brown, Haywood L ^e  

^a High Risk Pregnancy Center   (United States)

^b BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; GESTAGEN; MAGNESIUM SULFATE; GLUCOCORTICOID;

ANTIBIOTIC PROPHYLAXIS; CESAREAN SECTION; CONFERENCE PAPER; ECHOGRAPHY; FETUS MALFORMATION; GENETIC COUNSELING; GENETIC SCREENING; HEALTH CARE MANAGEMENT; HEALTH CARE QUALITY; HEALTH PROGRAM; HIGH RISK PREGNANCY; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; NATIONAL HEALTH ORGANIZATION; NEONATAL INTENSIVE CARE UNIT; OBSTETRIC DELIVERY; OBSTETRIC EMERGENCY; OBSTETRIC HEMORRHAGE; OUTPATIENT CARE; PREECLAMPSIA; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL SCREENING; PREVENTION AND CONTROL; PRIORITY JOURNAL; PUERPERIUM; QUALITY CONTROL; SEIZURE; SEPSIS; TRIAL OF LABOR; VAGINAL BIRTH AFTER CESAREAN; VENOUS THROMBOEMBOLISM; FEMALE; FETAL GROWTH RETARDATION; HYPERTENSION, PREGNANCY-INDUCED; MEDICAL SOCIETY; ORGANIZATION; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; PRENATAL DIAGNOSIS; STANDARDS; UNITED STATES;

ANTIBIOTIC PROPHYLAXIS; ASPIRIN; CESAREAN SECTION; CONGRESSES AS TOPIC; FEMALE; FETAL GROWTH RETARDATION; GENETIC COUNSELING; GENETIC TESTING; GLUCOCORTICOIDS; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MAGNESIUM SULFATE; NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (U.S.); PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY, HIGH-RISK; PREMATURE BIRTH; PRENATAL DIAGNOSIS; QUALITY OF HEALTH CARE; SEPSIS; SOCIETIES, MEDICAL; UNITED STATES; VAGINAL BIRTH AFTER CESAREAN; VENOUS THROMBOEMBOLISM;

EID: 85028451273     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2017.07.018     Document Type: Conference Paper

References (117)

1. Friedman, A.M., Ananth, C.V., Prendergast, E., D'Alton, M.E., Wright, J.D., Evaluation of third-degree and fourth-degree laceration rates as quality indicators. Obstet Gynecol 125 (2015), 927–937.
2. Howell, E.A., Zeitlin, J., Hebert, P.L., Balbierz, A., Egorova, N., Association between hospital-level obstetric quality indicators and maternal and neonatal morbidity. JAMA 312 (2014), 1531–1541.
3. National Academy of Sciences, Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. 2001, National Academy Press, Washington (DC).
4. Squires, D., Anderson, C., U.S. health care from a global perspective: spending, use of services, prices, and health in 13 countries. Issue Brief (Commonw Fund) 15 (2015), 1–15.
5. Kanavos, P., Ferrario, A., Vandoros, S., Anderson, G.F., Higher US branded drug prices and spending compared with other countries may stem partly from quick uptake of new drugs. Health Aff (Millwood) 32 (2013), 753–761.
6. International Federation of Health Plans. 2013 comparative price report: variation in medical and hospital prices by country. Available at: https://static1.squarespace.com/static/518a3cfee4b0a77d03a62c98/t/534fc9ebe4b05a88e5fbab70/1397737963288/2013+iFHP+FINAL+4+14+14.pdf. Accessed April 30, 2017.
7. Organization for Economic Cooperation and Development. Health at a glance 2015: OECD indicators. 2015, OECD Publishing, Paris, France Available at: http://stats.oecd.org/index.aspx?DataSetCode=HEALTH_STAT Accessed April 30, 2016.
8. Osborn, R., Moulds, D., Squires, D., Doty, M.M., Anderson, C., International survey of older adults finds shortcomings in access, coordination, and patient-centered care. Health Aff (Millwood) 33 (2014), 2247–2255.
9. Kassebaum, N.J., Bertozzi-Villa, A., Coggeshall, M.S., et al. Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384 (2014), 980–1004.
10. March of Dimes. Preterm birth: the financial impact on business. 2013. Available at: http://www.marchofdimes.org/materials/premature-birth-the-financial-impact-on-business.pdf. Accessed April 30, 2017.
11. Hamilton, B.E., Martin, J.A., Osterman, M.J., Curtin, S.C., Births: final data for 2013. Natl Vital Stat Rep 64 (2015), 1–65.
12. Beck, S., Wojdyla, S., Say, L., et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Org 88 (2010), 31–38.
13. Spong, C.Y., Iams, J., Goldenberg, R., Hauck, F.R., Willinger, M., Disparities in perinatal medicine preterm birth, stillbirth, and infant mortality. Obstet Gynecol 117 (2011), 948–955.
14. Esplin, M.S., O'Brien, E., Fraser, A., et al. Estimating recurrence of spontaneous preterm delivery. Obstet Gynecol 112 (2008), 516–523.
15. Iams, J.D., Goldenberg, R.L., Meis, P.J., et al. The length of the cervix and the risk of spontaneous premature delivery: National Institute of Child Health and Human Development Maternal-Fetal Medicine Unit Network. N Engl J Med 334 (1996), 567–572.
16. Berghella, V., Rafael, T.J., Szychowski, J.M., Rust, O.A., Owen, J., Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol 117 (2011), 663–671.
17. Owen, J., Hankins, G., Iams, J.D., et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am J Obstet Gynecol 201 (2009), 375.e1–375.e8.
18. Fonseca, E.B., Celik, E., Parra, M., Singh, M., Nicolaides, K.H., Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357 (2007), 462–469.
19. Hassan, S.S., Romero, R., Vidyadhari, D., et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 38 (2011), 18–31.
20. Son, M., Grobman, W.A., Ayala, N.K., Miller, E.S., A universal mid-trimester transvaginal cervical length screening program and its associated reduced preterm birth rate. Am J Obstet Gynecol 214 (2016), 365.e1–365.e5.
21. Khalifeh, A., Quist-Nelson, J., Berghella, V., Universal cervical length screening for preterm birth prevention in the United States. J Matern Fetal Neonatal Med 30 (2017), 1500–1503.
22. Hernandez-Andrade, E., Romero, R., Hussein, Y., et al. Transabdominal evaluation of uterine cervical length during pregnancy fails to identify a substantial number of women with a short cervix. J Matern Fetal Neonatal Med 25 (2012), 1682–1689.
23. Friedman, A., Srinivas, S., Elovitz, M., Wang, E., Schwartz, N., Can transabdominal ultrasound be used as a screening test for short cervical length?. Am J Obstet Gynecol 208 (2013), 190–197.
24. Meis, P.J., Klebanoff, M., Thom, E., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348 (2003), 2379–2385.
25. Orsulak, M.K., Block-Abraham, D., Gee, R.E., 17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population. ClinTher 37 (2015), 727–732.
26. Wilms, F.F., Vis, J.Y., Pattinaja, D.A., et al. Relationship between the time interval from antenatal corticosteroid administration until preterm birth and the occurrence of respiratory morbidity. Am J Obstet Gynecol 205 (2011), 49.e1–49.e7.
27. Peaceman, A.M., Bajaj, K., Kumar, P., Grobman, W.A., The interval between a single course of antenatal steroids and delivery and its association with neonatal outcomes. Am J Obstet Gynecol 193 (2005), 1165–1169.
28. Adams, T.M., Kinzler, W.L., Chavez, M.R., Fazzari, M.J., Vintzileos, A.M., Practice patterns in the timing of antenatal corticosteroids for fetal lung maturity. J Matern Fetal Neonatal Med 28 (2015), 1598–1601.
29. Adams, T.M., Kinzler, W.L., Chavez, M.R., Vintzileos, A.M., The timing of administration of antenatal corticosteroids in women with indicated preterm birth. Am J Obstet Gynecol 212 (2015), 645.e1–645.e4.
30. Levin, H.I., Ananth, C.V., Benjamin-Boamah, C., Siddiq, Z., Son, M., Friedman, A.M., Clinical indication and timing of antenatal corticosteroid administration at a single centre. BJOG 123 (2016), 409–414.
31. Wapner, R.J., Sorokin, Y., Thom, E.A., et al. Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 195 (2006), 633–642.
32. Thorp, J.A., Jones, P.G., Knox, E., Clark, R.H., Does antenatal corticosteroid therapy affect birth weight and head circumference?. Obstet Gynecol 99 (2002), 101–108.
33. Murphy, K.E., Hannah, M.E., Willan, A.R., et al. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial: MACS Collaborative Group. Lancet 372 (2008), 2143–2151.
34. Garite, T.J., Kurtzman, J., Maurel, K., Clark, R., Impact of a ‘rescue course’ of antenatal corticosteroids: a multicenter randomized placebo-controlled trial: Obstetrix Collaborative Research Network. Am J Obstet Gynecol 200 (2009), 248.e1–248.e9 [Published erratum appears in Am J Obstet Gynecol 2009;201:428.].
35. American College of Obstetricians and Gynecologists. Management of preterm labor: Practice Bulletin no. 171. Obstet Gynecol 128 (2016), e155–e164.
36. Rouse, D.J., Hirtz, D.G., Thom, E., et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 359 (2008), 895–905.
37. Costantine, M.M., Weiner, S.J., Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstet Gynecol 114 (2009), 354–364.
38. American College of Obstetricians and Gynecologists Committee on Obstetric Practice; Society for Maternal-Fetal Medicine. Committee Opinion no. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol 115 (2010), 669–671.
39. Patient safety checklist no. 7: magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol 120 (2012), 432–433.
40. Paneth, N., Kiely, J.L., Wallenstein, S., Marcus, M., Pakter, J., Susser, M., Newborn intensive care and neonatal mortality in low-birth-weight infants: a population study. N Engl J Med 307 (1982), 149–155.
41. Bode, M.M., O'Shea, T.M., Metzguer, K.R., Stiles, A.D., Perinatal regionalization and neonatal mortality in North Carolina, 1968-1994. Am J Obstet Gynecol 184 (2001), 1302–1307.
42. Chung, J.H., Phibbs, C.S., Boscardin, W.J., Kominski, G.F., Ortega, A.N., Needleman, J., The effect of neonatal intensive care level and hospital volume on mortality of very low birth weight infants. Med Care 48 (2010), 635–644.
43. Gould, J.B., Marks, A.R., Chavez, G., Expansion of community-based perinatal care in California. J Perinatol 22 (2002), 630–640.
44. Ghulmiyyah, L., Sibai, B., Maternal mortality from preeclampsia/eclampsia. Semin Perinatol 36 (2012), 56–59.
45. Ozimek, J.A., Eddins, R.M., Greene, N., et al. Opportunities for improvement in care among women with severe maternal morbidity. Am J Obstet Gynecol 215 (2016), 509.e1–509.e6.
46. Clark, S.L., Christmas, J.T., Frye, D.R., Meyers, J.A., Perlin, J.B., Maternal mortality in the United States: predictability and the impact of protocols on fatal postcesarean pulmonary embolism and hypertension-related intracranial hemorrhage. Am J Obstet Gynecol 211 (2014), 32.e1–32.e9.
47. Altman, D., Carroli, G., Duley, L., et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 359 (2002), 1877–1890.
48. Smith, J.M., Lowe, R.F., Fullerton, J., Currie, S.M., Harris, L., Felker-Kantor, E., An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth, 13, 2013, 34.
49. Henderson, J.T., Whitlock, E.P., O'Conner, E., Senger, C.A., Thompson, J.H., Rowland, M.G., Low-dose aspirin for the prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 160 (2014), 695–703.
50. ACOG Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists’ Task Force on hypertension in pregnancy. Obstet Gynecol 122 (2013), 1122–1131.
51. Ray, J.G., Vermeulen, M.J., Schull, M.J., Redelmeier, D.A., Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 366 (2005), 1797–1803.
52. Kestenbaum, B., Seliger, S.L., Easterling, T.R., et al. Cardiovascular and thromboembolic events following hypertensive pregnancy. Am J Kidney Dis 42 (2003), 982–989.
53. Brown, M.C., Best, K.E., Pearce, M.S., Waugh, J., Robson, S.C., Bell, R., Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis. Eur J Epidemiol 28 (2013), 1–19.
54. Callaway, L.K., Lawlor, D.A., O'Callaghan, M., Williams, G.M., Najman, J.M., McIntyre, H.D., Diabetes mellitus in the 21 years after a pregnancy that was complicated by hypertension: findings from a prospective cohort study. Am J Obstet Gynecol 197 (2007), 492.e1–492.e7.
55. Nippita, T.A., Lee, Y.Y., Patterson, J.A., et al. Variation in hospital caesarean section rates and obstetric outcomes among nulliparae at term: a population-based cohort study. BJOG 122 (2015), 702–711.
56. Spong, C.Y., Berghella, V., Wenstrom, K.D., Mercer, B.M., Saade, G.R., Preventing the first cesarean delivery: summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, and American College of Obstetricians and Gynecologists Workshop. Obstet Gynecol 120 (2012), 1181–1193.
57. Main, E.K., Moore, D., Farrell, B., et al. Is there a useful cesarean birth measure? Assessment of the nulliparous term singleton vertex cesarean birth rate as a tool for obstetric quality improvement. Am J Obstet Gynecol 194 (2006), 1644–1651.
58. Armstrong, J.C., Kozhimannil, K.B., McDermott, P., Saade, G.R., Srinivas, S.K., Society for Maternal-Fetal Medicine Health Policy Committee. Comparing variation in hospital rates of cesarean delivery among low-risk women using 3 different measures. Am J Obstet Gynecol 214 (2016), 153–163.
59. Geller, S.E., Ahmed, S., Brown, M.F., Cox, S.M., Rosenberg, D., Kilpatrick, S.J., International Classification of Diseases-9th revision coding for preeclampsia: how accurate is it?. Am J Obstet Gynecol 190 (2004), 1629–1633.
60. Korst, L.M., Gregory, K.D., Gornbein, J.A., Elective primary cesarean delivery: accuracy of administrative data. Paediatr Perinat Epidemiol 18 (2004), 112–119.
61. Main E, Castles A; California Maternal Quality Care Collaborative. A rational approach to reducing first-birth (NTSV) cesarean birth rates. Available at: http://www.hqinstitute.org/sites/main/files/file-attachments/ntsv_cs_reduction_san_diego.pdf. Accessed March 20, 2017.
62. Shields, L., Walker, S., Wiesner, S., et al. Cesarean section rates: side-by-side comparison of three national inpatient quality indicators. 37th Annual Meeting of the Society for Maternal-Fetal Medicine: The Pregnancy Meeting. 23 January 2017-28 January 2017. Am J Obstet Gynecol 216:suppl (2017), S37–S38.
63. Main EK, Morton CH, Hopkins D, Giuliani G, Melsop K, Gould JB. Cesarean deliveries, outcomes, and opportunities for change in California: Toward a public agenda for maternity care safety and quality. 2011. Palo Alto, CA: California Maternal Quality Care Collaborative. Available at: https://www.cmqcc.org/resource/cesarean-deliveries-outcomes-and-opportunities-change-california-toward-public-agenda. Accessed May 3, 2017.
64. Health Pacific Business Group on Health. Case study: Maternity payment and care redesign pilot. Published October 2015. Available at: http://www.pbgh.org/storage/documents/TMC_Case_Study_Oct_2015.pdf. Accessed May 3, 2017.
65. Barber, E.L., Lundsberg, L.S., Belanger, K., et al. Indications contributing to the increasing cesarean delivery rate. Obstet Gynecol 118 (2011), 29–38.
66. Gilbert, S.A., Grobman, W.A., Landon, M.B., et al. Lifetime cost-effectiveness of trial of labor after cesarean in the United States. Value Health 16 (2013), 953–964.
67. Cheng, E.R., Declercq, E.R., Belanoff, C., et al. Racial and ethnic differences in the likelihood of vaginal birth after cesarean delivery. Birth 42 (2015), 249–253.
68. Gregory, K.D., Fridman, M., Korst, L., Trends and patterns of vaginal birth after cesarean availability in the United States. Semin Perinatol 34 (2010), 237–243.
69. Landon, M.B., Spong, C.Y., Thom, E., et al. Risk of uterine rupture with a trial of labor in women with multiple and single prior cesarean delivery. Obstet Gynecol 108 (2006), 12–20.
70. Friedman, A.M., Srinivas, S.K., Is documentation of TOLAC counseling a good measure of quality of care?. J Matern Fetal Neonatal Med 29 (2016), 1710–1714.
71. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus no. 1: safe prevention of the primary cesarean delivery. Obstet Gynecol 123 (2014), 693–711.
72. Boyle, A., Reddy, U.M., Landy, H.J., Huang, C.C., Driggers, R.W., Laughon, S.K., Primary cesarean delivery in the United States. Obstet Gynecol 122 (2013), 33–40.
73. Barber, E.L., Lundsberg, L.S., Belanger, K., Pettker, C.M., Funai, E.F., Illuzzi, J.L., Indications contributing to the increasing cesarean delivery rate. Obstet Gynecol 118 (2011), 29–38.
74. Hendrix, N.W., Chauhan, S.P., Scardo, J.A., Ellings, J.M., Devoe, L.D., Managing nonreassuring fetal heart rate patterns before cesarean delivery: compliance with ACOG recommendations. J Reprod Med 45 (2000), 995–999.
75. Chang, J., Elam-Evans, L.D., Berg, C.J., et al. Pregnancy-related mortality surveillance–United States, 1991-1999. MMWR Surveill Summ 52 (2003), 1–8.
76. MacKeen, A.D., Packard, R.E., Ota, E., Berghella, V., Baxter, J.K., Timing of intravenous prophylactic antibiotics for preventing postpartum infectious morbidity in women undergoing cesarean delivery. Cochrane Database Syst Rev, 12, 2014, CD009516.
77. Smaill, F.M., Grivell, R.M., Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev, 10, 2014, CD007482.
78. Chelmow, D., Hennesy, M., Evantash, E.G., Prophylactic antibiotics for non-laboring patients with intact membranes undergoing cesarean delivery: an economic analysis. Am J Obstet Gynecol 191 (2004), 1661–1665.
79. Creanga, A.A., Berg, C.J., Syverson, C., Seed, K., Bruce, F.C., Callaghan, W.M., Pregnancy-related mortality in the United States, 2006-2010. Obstet Gynecol 125 (2015), 5–12.
80. MacDougall, D.A., Feliu, A.L., Boccuzzi, S.J., Lin, J., Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 63:suppl 6 (2006), S5–S15.
81. Palmerola, K.L., D'Alton, M.E., Brock, C.O., Friedman, A.M., A comparison of recommendations for pharmacologic thromboembolism prophylaxis after caesarean delivery from three major guidelines. BJOG 123 (2016), 2157–2162.
82. Callaghan, W.M., Grobman, W.A., Kilpatrick, S.J., Main, E.K., D'Alton, M.D., Facility-based identification of women with severe maternal morbidity: it's time to start. Obstet Gynecol 123 (2014), 978–981.
83. Severe maternal morbidity: clarification of the new joint commission sentinel event policy [statement]. Washington, DC: American College of Obstetricians and Gynecologists; Washington, DC: Association of Women's Health, Obstetrics, and Neonatal Nurses; Oakbrook Terrace, IL: The Joint Commission; Washington, DC: Society for Maternal-Fetal Medicine. January 28, 2015. Available at: https://www.acog.org/About-ACOG/News-Room/Statements/2015/Severe-Maternal-Morbidity-Clarification-of-the-New-Joint-Commission-Sentinel-Event-Policy. Accessed May 25, 2016.
84. Lyndon A, Lagrew D, Shields L, Main E, Cape V. Improving health care response to obstetric hemorrhage: a California Maternal Quality Care Collaborative toolkit to transform maternity care. Version 2.0. March 2015. Available at: https://www.cmqcc.org/resources-tool-kits/toolkits/ob-hemorrhage-toolkit. Accessed May 4, 2017.
85. Silver, R.M., Fox, K.A., Barton, J.R., et al. Center of excellence for placenta accreta. Am J Obstet Gynecol 212 (2015), 561–568.
86. Bingham, D., Scheich, B., Byfield, R., Wilson, B., Bateman, B.T., Postpartum hemorrhage preparedness elements vary among hospitals in New Jersey and Georgia. Obstet Gynecol Neonatal Nurs 45 (2016), 227–238.
87. Shields, L.E., Smalarz, K., Reffigee, L., Mugg, S., Burdumy, T.J., Propst, M., Comprehensive maternal hemorrhage protocols improve patient safety and reduce utilization of blood products. Am J Obstet Gynecol 205 (2011), 368.e1–368.e8.
88. Bailit, J.L., Grobman, W.A., McGee, P., et al. Does the presence of a condition-specific obstetric protocol lead to detectable improvements in pregnancy outcomes?. Am J Obstet Gynecol 213 (2015), 86.e1–86.e6.
89. Bauer, M.E., Bateman, B.T., Bauer, S.T., Shanks, A.M., Mhyre, J.M., Maternal sepsis mortality and morbidity during hospitalization for delivery: Temporal trends and independent associations for severe sepsis. Anesth Analg 117 (2013), 944–950.
90. Pollock, W., Rose, L., Dennis, C.L., Pregnant and postpartum admissions to the intensive care unit: a systematic review. Intensive Care Med 36 (2010), 1465–1474.
91. Dellinger, R.P., Levy, M.M., Rhodes, A., et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012. Crit Care Med 39 (2013), 165–228.
92. Gatewood, M.O., Wemple, M., Greco, S., Kritek, P.A., Durvasula, R., A quality improvement project to improve early sepsis care in the emergency department. BMJ Qual Saf 24 (2015), 787–795.
93. Lappen, J.R., Keene, M., Lore, M., Grobman, W.A., Gossett, D.R., Existing models fail to predict sepsis in an obstetric population with intrauterine infection. Am J Obstet Gynecol 203 (2010), 573.e1–573.e5.
94. Albright, C.M., Ali, T.N., Lopes, V., Rouse, D.J., Anderson, B.L., The sepsis in obstetrics score: a model to identify risk of morbidity from sepsis in pregnancy. Am J Obstet Gynecol 211 (2014), 39.e1–39.e8.
95. Rhee, C.1, Murphy, M.V., Li, L., Platt, R., Klompas, M., Centers for Disease Control and Prevention Epicenters Program. Lactate testing in suspected sepsis: trends and predictors of failure to measure levels. Crit Care Med 43 (2015), 1669–1676.
96. Sterling, S.A., Miller, W.R., Pryor, J., Puskarich, M.A., Jones, A.E., The impact of timing of antibiotics on outcomes in severe sepsis and septic shock: a systematic review and meta-analysis. Crit Care Med 43 (2015), 1907–1915.
97. Kramer, R.D., Cooke, C.R., Liu, V., Miller, R.R. 3rd, Iwashyna, T.J., Variation in the contents of sepsis bundles and quality measures: a systematic review. Ann Am Thorac Soc 12 (2015), 1676–1684.
98. Levy, M.M., Rhodes, A., Phillips, G.S., et al. Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Intensive Care Med 40 (2014), 1623–1633.
99. O'Keeffe, D.F., Abuhamad, A., Obstetric ultrasound utilization in the United States: data from various health plans. Semin Perinatol 37 (2013), 292–294.
100. Iriye, B., Hancock, L., Hancock, J., Ghamsary, M., Large variation in umbilical artery Doppler ultrasound (UAD) between MFM providers: results of the AMFMM RVU study. Am J Obstet Gynecol, 214(suppl), 2016, S435.
101. Iriye, B., Hancock, L., Ghamsary, M., Hancock, J., Second and third trimester ultrasound utilization in MFM practices: results of the AMFMM RVU study. Am J Obstet Gynecol, 214(suppl), 2016, S434.
102. Abuhamad, A.Z., Benacerraf, B.R., Woletz, P., Burke, B.L., The accreditation of ultrasound practices: impact on compliance with minimum performance guidelines. J Ultrasound Med 23 (2004), 1023–1029.
103. Boyd, P.A., Tonks, A.M., Rankin, J., et al. Monitoring the prenatal detection of structural fetal congenital anomalies in England and Wales: register-based study. J Med Screen 18 (2011), 2–7.
104. Acherman, R.J., Evans, W.N., Luna, C.F., et al. Prenatal detection of congenital heart disease in southern Nevada: the need for universal fetal cardiac evaluation. J Ultrasound Med 26 (2007), 1715–1719.
105. Van der Linde, D., Konings, E.E., Slager, M.A., et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol 58 (2011), 2241–2247.
106. Roger, V.L., Go, A.S., Lloyd-Jones, D.M., et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125 (2012), e2–e220.
107. Verheijen, P.M., Lisowski, L.A., Stoutenbeek, P., et al. Prenatal diagnosis of congenital heart disease affects preoperative acidosis in the newborn patient. J Thorac Cardiovasc Surg 121 (2001), 798–803.
108. Holland, B.J., Myers, J.A., Woods, C.R. Jr., Prenatal diagnosis of critical congenital heart disease reduces risk of death from cardiovascular compromise prior to planned neonatal cardiac surgery: a meta-analysis. Ultrasound Obstet Gynecol 45 (2015), 631–638.
109. Peterson, C., Ailes, E., Riehle-Colarusso, T., et al. Late detection of critical congenital heart disease among US infants: Estimation of the potential impact of proposed universal screening using pulse oximetry. JAMA Pediatr 168 (2014), 361–370.
110. Lindqvist, P.G., Molin, J., Does antenatal identification of small-for-gestational age fetuses significantly improve their outcome?. Ultrasound Obstet Gynecol 25 (2005), 258–264.
111. Society for Maternal-Fetal Medicine Publications Committee, Berkley, E., Chauhan, S.P., Abuhamad, A., Doppler assessment of the fetus with intrauterine growth restriction. Am J Obstet Gynecol 206 (2012), 300–308.
112. Zellerino, B.C., Milligan, S.A., Gray, J.R., Williams, M.S., Brooks, R., Identification and prioritization of quality indicators in clinical genetics: an international survey. Am J Med Genet C Semin Med Genet 151C (2009), 179–190.
113. Donnelly, J.C., Platt, L.D., Rebarber, A., Zachary, J., Grobman, W.A., Wapner, R.J., Association of copy number variants with specific ultrasonographically detected fetal anomalies. Obstet Gynecol 124 (2014), 83–90.
114. Callaway, J.L., Shaffer, L.G., Chitty, L.S., Rosenfeld, J.A., Crolla, J.A., The clinical utility of microarray technologies applied to prenatal cytogenetics in the presence of a normal conventional karyotype: a review of the literature. Prenat Diagn 33 (2013), 1119–1123.
115. Mitchell, C., Lawton, E., Morton, C., McCain, C., Holtby, S., Main, E., California Pregnancy-Associated Mortality Review: mixed methods approach for improved case identification, cause of death analyses and translation of findings. Matern Child Health J 18 (2014), 518–526.
116. American College of Obstetricians and Gynecologists. Leading health organizations launch state-based care programs through the Alliance for Innovation on Maternal Health. June 4, 2015. Available at: http://www.acog.org/About-ACOG/News-Room/News-Releases/2015/Leading-Health-Organizations-Launch-State-Based-Care-Programs-Through-theAIM-on-Maternal-Health. Accessed June 12, 2017.
117. California Department of Public Health, Center for Family Health, Maternal, Child and Adolescent Health Division, April 2013. Maternal mortality rate. Available at: https://archive.cdph.ca.gov/data/statistics/Documents/2013MaternalMortalityRates-SlideSet%20for%20MCAH%20Website.pdf. Accessed June 12, 2017.